Evidence map›Paper›PMID 36504888›Full record

ArticleAmerican journal of cancer research2022

In vivo growth of subclones derived from Lewis lung carcinoma is determined by the tumor microenvironment.

Ben-Ling Xu, Xiao-Ming Wang, Guang-Yu Chen, Peng Yuan, Lu Han, Peng Qin, Tie-Peng Li, Hong-Qin You, Cheng-Juan Zhang, Xiao-Min Fu and 3 more

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Exploring heterogeneity: a dive into preclinical models of cancer cachexia.American journal of physiology. Cell physiology · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Ben-Ling XuDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou 450008, Henan, P. R. China.
Xiao-Ming WangDepartment of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou 450008, Henan, P. R. China.
Guang-Yu ChenDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou 450008, Henan, P. R. China.
Peng YuanDepartment of Breast Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou 450008, Henan, P. R. China.
Lu HanDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou 450008, Henan, P. R. China.
Peng QinDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou 450008, Henan, P. R. China.
Tie-Peng LiDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou 450008, Henan, P. R. China.
Hong-Qin YouDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou 450008, Henan, P. R. China.
Cheng-Juan ZhangCenter of Bio Repository, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou 450008, Henan, P. R. China.
Xiao-Min FuDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou 450008, Henan, P. R. China.
Long YuanDepartment of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou 450008, Henan, P. R. China.
Zi-Bing WangDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou 450008, Henan, P. R. China.
Quan-Li GaoDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou 450008, Henan, P. R. China.
Henan Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heterogeneity is a fundamental feature of human tumors and plays a major role in drug resistance and disease progression. In the present study, we selected single-cell-derived cell lines (SCDCLs) derived from Lewis lung carcinoma (LLC1) cells to investigate tumorigenesis and heterogeneity. SCDCLs were generated using limiting dilution. Five SCDCLs were subcutaneously injected into wild-type C57BL/6N mice; however, they displayed significant differences in tumor growth. Subclone SCC1 grew the fastest in vivo, whereas it grew slower in vitro. The growth pattern of SCC2 was the opposite to that of SCC1. Genetic differences in these two subclones showed marked differences in cell adhesion and proliferation. Pathway enrichment results indicate that signal transduction and immune system responses were the most significantly altered functional categories in SCC2 cells compared to those in SCC1 cells in vitro. The number and activation of CD3

Indexed as

Cancer cell lineheterogeneityimmunological characterizationLewis lung carcinomasingle cell-derived cell lines

Identifiers

PMID36504888
PMCPMC9729899
OpenAlexW4311290266

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.